UK markets closed

BMEA May 2024 22.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.35000.0000 (0.00%)
As of 10:22AM EDT. Market open.
Full screen
Previous close0.3500
Open0.3500
Bid0.0000
Ask0.7500
Strike22.50
Expiry date2024-05-17
Day's range0.3500 - 0.3500
Contract rangeN/A
Volume4
Open interest276
  • GlobeNewswire

    Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on May 1, 2024, the compensation committee of Biomea’s board of directors granted 8 new employees non-qualified stock options to purchase an aggregate of 80,250 shares of th

  • GlobeNewswire

    Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

    BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes The first two type 1 diabetes patients enrolled in COVALENT-112 both demonstrated early signs of clinical activity with improved measures of beta-cell function after initial treatment with BMF-219BMF-219 has been well tolerated by both patientsOpen label portion of Phase II COVALENT-112 study readout of 40 patients with type 1 diabetes dosed for 12 weeks

  • GlobeNewswire

    Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

    In 2023, reported Phase 2 data (COVALENT-111) in type 2 diabetes patients supporting the disease-modifying potential of BMF-219 to address a root cause of diabetes: a loss of healthy, insulin-producing beta cells. After just a 4-week treatment period in type 2 diabetes patients, who had previously failed standard of care (HbA1c > 7.0% and < 10%), BMF-219 demonstrated continued glycemic control at 26 weeks, or five months, after cessation of dosing.Enrollment underway in COVALENT-111 expansion co